AU2017311691B2 - Piperazine derivatives, pharmaceutical compositions and methods of use thereof - Google Patents

Piperazine derivatives, pharmaceutical compositions and methods of use thereof Download PDF

Info

Publication number
AU2017311691B2
AU2017311691B2 AU2017311691A AU2017311691A AU2017311691B2 AU 2017311691 B2 AU2017311691 B2 AU 2017311691B2 AU 2017311691 A AU2017311691 A AU 2017311691A AU 2017311691 A AU2017311691 A AU 2017311691A AU 2017311691 B2 AU2017311691 B2 AU 2017311691B2
Authority
AU
Australia
Prior art keywords
cancer
compound
carcinoma
formula
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017311691A
Other languages
English (en)
Other versions
AU2017311691A1 (en
Inventor
Oren Menahem BECKER
Vered Behar
Paul Salama
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vidac Pharma Ltd
Original Assignee
Vidac Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vidac Pharma Ltd filed Critical Vidac Pharma Ltd
Publication of AU2017311691A1 publication Critical patent/AU2017311691A1/en
Application granted granted Critical
Publication of AU2017311691B2 publication Critical patent/AU2017311691B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/38—[b, e]-condensed with two six-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
    • C07D335/04—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D335/10—Dibenzothiopyrans; Hydrogenated dibenzothiopyrans
    • C07D335/12—Thioxanthenes
    • C07D335/14—Thioxanthenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 9
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyrane Compounds (AREA)
  • Indole Compounds (AREA)
AU2017311691A 2016-08-18 2017-08-17 Piperazine derivatives, pharmaceutical compositions and methods of use thereof Active AU2017311691B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662376396P 2016-08-18 2016-08-18
US62/376,396 2016-08-18
PCT/IL2017/050909 WO2018033918A1 (en) 2016-08-18 2017-08-17 Piperazine derivatives, pharmaceutical compositions and methods of use thereof

Publications (2)

Publication Number Publication Date
AU2017311691A1 AU2017311691A1 (en) 2019-04-04
AU2017311691B2 true AU2017311691B2 (en) 2021-12-02

Family

ID=61196523

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017311691A Active AU2017311691B2 (en) 2016-08-18 2017-08-17 Piperazine derivatives, pharmaceutical compositions and methods of use thereof

Country Status (6)

Country Link
US (2) US11084807B2 (https=)
JP (1) JP7471818B2 (https=)
CN (1) CN109641884B (https=)
AU (1) AU2017311691B2 (https=)
CA (1) CA3034211A1 (https=)
WO (1) WO2018033918A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11084807B2 (en) * 2016-08-18 2021-08-10 Vidac Pharama Ltd. Piperazine derivatives, pharmaceutical compositions and methods of use thereof
US10682346B2 (en) 2016-11-07 2020-06-16 Vidac Pharma Ltd. Use of hexokinase 2/mitochondria-detaching compounds for activating immune responses
EP4464334A3 (en) 2016-11-07 2025-01-08 VIDAC Pharma Ltd. Use of compounds for treating hk2-expressing cancers
EP3554494A4 (en) 2016-12-19 2021-02-17 Cellixbio Private Limited INFLAMMATION TREATMENT COMPOSITIONS AND METHODS
CN110003204B (zh) * 2019-04-30 2020-08-11 上海勋和医药科技有限公司 一种bet蛋白抑制剂、其制备方法及用途
WO2025163633A1 (en) * 2024-01-30 2025-08-07 Vidac Pharma Ltd. Synergistic therapies for treating cancer
CN118063410B (zh) * 2024-03-04 2026-03-13 河南省锐达医药科技有限公司 一种哌嗪萘甲酰胺类化合物、其制备方法及应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03251564A (ja) * 1990-02-26 1991-11-11 Taisho Pharmaceut Co Ltd ジメチルカルバゾール誘導体
US6071901A (en) * 1994-01-04 2000-06-06 Novo Nordisk A/S Substituted dibenz[b,f]azepines and uses thereof
US20040097734A1 (en) * 2002-06-29 2004-05-20 Matthias Gerlach Aryl- and heteroarylcarbonylpiperazines and their use for the treatment of benign and malignant oncoses

Family Cites Families (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2742472A (en) 1956-04-17 Spasmolytic pipergzjnes
FR6541E (fr) 1906-12-17 Paul Charles Louis Aime Joseph Chambre d'encolleuse économique à grande production
BE486462A (https=)
NL71566C (https=) 1948-10-30
GB666457A (en) 1948-10-30 1952-02-13 Henri Morren Carbonyl chlorides and monocarboxyamides of piperazine and process for the preparation thereof
GB748812A (en) 1952-12-15 1956-05-09 Abbott Lab Improvements in or relating to piperazine derivatives and process of preparing the same
CH333366A (de) 1953-09-04 1958-10-15 Ciba Geigy Verfahren zur Herstellung neuer Pyridazone
DE954155C (de) 1954-01-08 1956-12-13 Schering Ag Verfahren zur Herstellung von 4-Aminochromanen
GB773756A (en) 1954-08-18 1957-05-01 Searle & Co 9-aminoalkyl-9-xanthenecarboxamides and derivatives thereof
GB781528A (en) 1954-09-10 1957-08-21 American Cyanamid Co Substituted ethylene dipiperazines
GB778309A (en) 1954-11-12 1957-07-03 Rhone Poulenc Sa 4-o.o-diphenyl-phosphorylamido-pyrazolones
NL92955C (https=) 1954-12-23
GB777209A (en) 1954-12-28 1957-06-19 Wellcome Found Improvements in or relating to piperazine derivatives
US2838509A (en) 1956-10-02 1958-06-10 Searle & Co 9-aminoalkyl-9-xanthenecarboxamides
FR1192168A (fr) 1957-04-11 1959-10-23 Préparation de la nu-thiodiphénylcarbamyl piperazine
US2887481A (en) 1957-04-29 1959-05-19 Schering Corp Heterocyclic amides
US3284449A (en) 1964-12-29 1966-11-08 Searle & Co Hydrazones of 1-amino-4-xanthenecar-bonylpiperazines
NL129629C (https=) 1965-07-02
FR6541M (https=) 1967-05-10 1968-12-16
US3700658A (en) 1967-07-05 1972-10-24 Adolf Steinhofer N-alkyl-n-arylcarbamoyl lactams
US3585171A (en) 1967-07-05 1971-06-15 Basf Ag Accelerating the anionic polymerization of lactams
DE1720281A1 (de) 1967-07-05 1971-06-09 Basf Ag Verfahren zum Beschleunigen der anionischen Polymerisation von Lactamen
DE1770968A1 (de) 1968-07-24 1972-01-13 Bayer Ag Verfahren zur Herstellung von Polyamiden
GB1282336A (en) 1970-03-25 1972-07-19 Rech S Et D Applic Scient Soge Thiaxanthene derivatives and their preparation
US3803141A (en) 1972-08-14 1974-04-09 Burdick & Jackson Labor Inc 10-(1-substituted-3-pyrrolidylmethyl)phenothiazines
US3838118A (en) * 1973-02-20 1974-09-24 Janssen Pharmaceutica Nv ((thioxanthenyl)propyl)-piperidyl-benzimidazolinones
FR2218100A1 (en) * 1973-02-20 1974-09-13 Janssen Pharmaceutica Nv Neuroleptic tricyclic derivs. - of benzimidazolinones and triazaspiro-4,5-decan-4-ones
DE2519583A1 (de) 1975-05-02 1976-11-18 Basf Ag Thermoplastische polybutylenterephthalat-formmassen
JPS5334779A (en) 1976-09-09 1978-03-31 Kissei Pharmaceut Co Ltd Novel piperazine derivatives and thier preparation
US4188485A (en) 1978-06-16 1980-02-12 G. D. Searle & Co. 1-[(10,11-Dihydro-5H-dibenzo[a,d]-cyclohepten-5-yl)methyl]-4-substituted piperidines and related compounds
CH653675A5 (en) 1983-05-26 1986-01-15 Ciba Geigy Ag Microbicides
DE3607194A1 (de) 1986-03-05 1987-09-10 Merck Patent Gmbh Carbamoylphenothiazine
US4812462A (en) 1986-04-01 1989-03-14 Warner-Lambert Company 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-6-carboxylic acid analogs having antihypertensive activity
US5223508A (en) 1988-12-27 1993-06-29 Kirin Beer Kabushiki Kaisha Pyridyl carboximidamide compounds useful in treating blood pressure
JPH04130429A (ja) 1990-09-21 1992-05-01 Konica Corp ハロゲン化銀写真感光材料
JP2696434B2 (ja) 1991-01-23 1998-01-14 富士写真フイルム株式会社 画像形成方法
JPH04356466A (ja) 1991-01-28 1992-12-10 Mitsui Toatsu Chem Inc 新規キノリン誘導体及びそれを有効成分として含有する制癌剤効果増強剤
JPH05273701A (ja) 1992-03-26 1993-10-22 Konica Corp ハロゲン化銀カラー写真感光材料
DE4215213A1 (de) 1992-05-09 1993-11-11 Merck Patent Gmbh Arylacetamide
JPH06211664A (ja) 1993-01-20 1994-08-02 Pola Chem Ind Inc 薬剤に対する感受性回復剤
US5599815A (en) 1993-02-04 1997-02-04 Meiji Seika Kabushiki Kaisha Antipsychotic benzoisothiazolyl piperazine derivatives
JPH06228095A (ja) 1993-02-04 1994-08-16 Kirin Brewery Co Ltd カルバゾール誘導体
WO1994022842A1 (en) 1993-03-29 1994-10-13 Basf Aktiengesellschaft 1-amino-3-phenoxy propane derivatives as modulators of multi-drug resistance
DE69422306T4 (de) 1993-11-30 2000-09-07 G.D. Searle & Co., Chicago Substituierte pyrazolyl-benzolsulfonamide zur behandlung von entzündungen
US5466823A (en) 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
DE4430091A1 (de) 1994-08-25 1996-02-29 Bayer Ag Verwendung von N-substituierten Phenothiazinen
JPH08110621A (ja) 1994-10-12 1996-04-30 Fuji Photo Film Co Ltd ハロゲン化銀カラー感光材料
JPH08217758A (ja) 1995-02-09 1996-08-27 Nissan Chem Ind Ltd ４−ハロアルキルピリミジン−５−カルボン酸アニライド誘導体
UA54385C2 (uk) * 1995-04-07 2003-03-17 Ново Нордіск А/С N-заміщені азагетероциклічні карбонові кислоти та їх ефіри, спосіб їх одержання, фармацевтична композиція та спосіб лікування
US5795894A (en) 1995-05-02 1998-08-18 Schering Corporation Piperazino derivatives as neurokinn antagonists
WO1997046549A1 (en) 1996-06-05 1997-12-11 Novartis Ag Anti-neurodegeneratively effective xanthene derivatives
JP2959765B2 (ja) 1997-12-12 1999-10-06 日本たばこ産業株式会社 ３−ピペリジル−４−オキソキナゾリン誘導体及びそれを含有してなる医薬組成物
JPH11292840A (ja) 1998-04-06 1999-10-26 Soyaku Gijutsu Kenkyusho:Kk ノルスタチン誘導体又はその塩
TW593241B (en) 1999-04-20 2004-06-21 Hoffmann La Roche Carbamic acid derivatives
EP1236726B1 (en) 1999-12-03 2004-12-01 Ono Pharmaceutical Co., Ltd. Triazaspiro 5.5]undecane derivatives and drugs containing the same as the active ingredient
US6436972B1 (en) 2000-04-10 2002-08-20 Dalhousie University Pyridones and their use as modulators of serine hydrolase enzymes
GB0012362D0 (en) 2000-05-22 2000-07-12 Aventis Pharma Ltd Chemical compounds
CA2310205A1 (en) 2000-05-29 2001-11-29 Dalhousie University Unknown
DE10035928A1 (de) * 2000-07-21 2002-03-07 Asta Medica Ag Neue Heteroaryl-Derivate und deren Verwendung als Arzneimittel
JP2002047272A (ja) 2000-07-26 2002-02-12 Dai Ichi Seiyaku Co Ltd ポリアミンアミド誘導体
CA2418720A1 (en) 2000-09-13 2002-03-21 Vertex Pharmaceuticals Incorporated Caspase inhibitors and uses thereof
US6727364B2 (en) 2001-04-30 2004-04-27 The Procter & Gamble Company Triazole compounds useful in treating diseases associated with unwanted cytokine activity
AU2003225088A1 (en) 2002-04-19 2003-11-03 Vertex Pharmaceuticals Incorporated Regulation of tnf-alpha
US7161003B1 (en) 2002-09-04 2007-01-09 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
US8673924B2 (en) 2002-09-04 2014-03-18 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors
US8580782B2 (en) 2002-09-04 2013-11-12 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors
US7196078B2 (en) 2002-09-04 2007-03-27 Schering Corpoartion Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors
MXPA05002571A (es) 2002-09-04 2005-09-08 Schering Corp Pirazolopirimidinas como inhibidores de cinasa dependientes de ciclina.
GB0224084D0 (en) 2002-10-16 2002-11-27 Glaxo Group Ltd Novel compounds
EP1571146A4 (en) 2002-12-10 2010-09-01 Ono Pharmaceutical Co NITROGENIC HETEROCYCLIC COMPOUNDS AND THEIR MEDICAL USE
US20040147502A1 (en) 2002-12-17 2004-07-29 Bisacchi Gregory S. Beta lactam compounds and their use as inhibitors of tryptase
DE10348023A1 (de) 2003-10-15 2005-05-19 Imtm Gmbh Neue Alanyl-Aminopeptidasen-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen
US7700603B2 (en) 2003-12-15 2010-04-20 Schering Corporation Heterocyclic aspartyl protease inhibitors
EP2335701B1 (en) 2003-12-15 2012-07-11 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7592348B2 (en) 2003-12-15 2009-09-22 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7763609B2 (en) 2003-12-15 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
US9016221B2 (en) 2004-02-17 2015-04-28 University Of Florida Research Foundation, Inc. Surface topographies for non-toxic bioadhesion control
WO2005111025A1 (en) 2004-04-29 2005-11-24 Aventis Pharmaceuticals Inc. 3-piperidinylisochroman-5-ols as dopamine agonists
CA2567080A1 (en) 2004-05-27 2005-12-15 Vertex Pharmaceuticals Incorporated Ice inhibitors for the treatment of autoinflammatory diseases
WO2006071958A1 (en) 2004-12-29 2006-07-06 Millennium Pharmaceuticals, Inc. Compounds useful as chemokine receptor antagonists
GB0500300D0 (en) 2005-01-07 2005-02-16 Ionix Pharmaceuticals Ltd Chemical compositions
WO2006105056A2 (en) 2005-03-28 2006-10-05 Fmc Corporation Insecticidal 2,4-diaminoquinazolines and related derivatives
DE102005044813A1 (de) 2005-05-19 2007-10-04 Grünenthal GmbH Substituierte Spiro-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln
WO2007008541A2 (en) 2005-07-08 2007-01-18 Kalypsys, Inc. Cellular cholesterol absorption modifiers
CA2617042A1 (en) 2005-07-29 2007-02-01 Takeda Pharmaceutical Company Limited Spiro-cyclic compound
EP1960364A2 (en) 2005-12-07 2008-08-27 Ramot at Tel-Aviv University Ltd. Chemical derivatives of jasmonate, pharmaceutical compositions and methods of use thereof
WO2007076055A2 (en) * 2005-12-22 2007-07-05 Entremed, Inc. Compositions and methods comprising proteinase activated receptor antagonists
WO2007098086A2 (en) 2006-02-17 2007-08-30 Avalon Pharmaceuticals Hydroxypiperidine derivatives and uses thereof
US20080051387A1 (en) 2006-06-09 2008-02-28 Yuelian Xu Tetrahydropyrido[3,4-d]pyrimidines and related analogues
GB0614365D0 (en) 2006-07-19 2006-08-30 Proaxon Ltd Pharmaceutical compositions and their use
AU2007275415A1 (en) 2006-07-20 2008-01-24 Ligand Pharmaceuticals Incorporated Proline urea CCR1 antagonists for the treatment of autoimmune diseases or inflammation
EP2060563A4 (en) 2006-09-08 2010-12-22 Dainippon Sumitomo Pharma Co CYCLIC AMINO ALKYL CY CARBOXYL AMIDE DERIVATIVE
RU2329044C1 (ru) 2006-11-16 2008-07-20 Андрей Александрович Иващенко Лиганды 5-ht6 рецепторов, фармацевтическая композиция, способ ее получения и лекарственное средство
US8202891B2 (en) 2007-04-24 2012-06-19 Theravance, Inc. Quaternary ammonium compounds useful as muscarinic receptor antagonists
JP2011504499A (ja) 2007-11-21 2011-02-10 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ トリプターゼ阻害剤として使用するためのスピロピペリジン
US8017617B2 (en) 2007-12-14 2011-09-13 Theravance, Inc. Amidine-containing compounds useful as muscarinic receptor antagonists
WO2009086303A2 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
JP5538239B2 (ja) 2008-02-12 2014-07-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ベンゾモルファン及び関連骨格の尿素誘導体、そのような化合物を含む医薬ならびにそれらの使用
EP2334680A2 (en) 2008-08-20 2011-06-22 Sequoia Pharmaceuticals, Inc. Hcv protease inhibitors
EP2411526A4 (en) 2009-03-27 2012-09-19 Zacharon Pharmaceuticals Inc MODULATORS OF GANGLIOSID BIOSYNTHESIS
WO2010137738A1 (en) 2009-05-28 2010-12-02 Otsuka Pharmaceutical Co., Ltd. Heterocyclic compounds for the treatment of stress-related conditions
CA2798330A1 (en) 2010-05-05 2011-11-10 Infinity Pharmaceuticals, Inc. Tetrazolones as inhibitors of fatty acid synthase
TW201236239A (en) 2010-11-16 2012-09-01 Solvay Rechargeable metal or metal-ion cell
JP2012111731A (ja) 2010-11-26 2012-06-14 Otsuka Pharmaceut Co Ltd 医薬
WO2012080729A2 (en) 2010-12-14 2012-06-21 Electrophoretics Limited CASEIN KINASE 1δ (CK1δ) INHIBITORS
CN102690717B (zh) 2011-03-24 2014-08-20 中国石油化工股份有限公司 一种极压长寿命汽轮机润滑油组合物
CA2830958A1 (en) 2011-04-06 2012-10-11 The Scripps Research Institute N1- and n2-carbamoyl-1,2,3-triazole serine hydrolase inhibitors and methods
US9326973B2 (en) 2012-01-13 2016-05-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US20150023913A1 (en) 2013-07-02 2015-01-22 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
WO2015005901A1 (en) 2013-07-09 2015-01-15 Bristol-Myers Squibb Company Combinations of hepatitis c virus inhibitors
CN103896990B (zh) 2014-03-12 2017-02-08 石家庄诚志永华显示材料有限公司 有机电致发光材料及其应用
CN104109134A (zh) 2014-06-26 2014-10-22 陕西科技大学 一种n-酰基吩噻嗪及其制备方法
CN104109133A (zh) 2014-06-26 2014-10-22 陕西科技大学 一种制备n-酰基吩噻嗪的方法
CN104497013B (zh) 2014-12-11 2017-05-31 石家庄诚志永华显示材料有限公司 氮杂咔唑类oled材料及其制备方法与应用
CN104557875A (zh) 2015-01-21 2015-04-29 石家庄诚志永华显示材料有限公司 茚并吲哚环状化合物与在有机发光二极管中的应用
US11084807B2 (en) * 2016-08-18 2021-08-10 Vidac Pharama Ltd. Piperazine derivatives, pharmaceutical compositions and methods of use thereof
EP4464334A3 (en) * 2016-11-07 2025-01-08 VIDAC Pharma Ltd. Use of compounds for treating hk2-expressing cancers
US10682346B2 (en) 2016-11-07 2020-06-16 Vidac Pharma Ltd. Use of hexokinase 2/mitochondria-detaching compounds for activating immune responses

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03251564A (ja) * 1990-02-26 1991-11-11 Taisho Pharmaceut Co Ltd ジメチルカルバゾール誘導体
US6071901A (en) * 1994-01-04 2000-06-06 Novo Nordisk A/S Substituted dibenz[b,f]azepines and uses thereof
US20040097734A1 (en) * 2002-06-29 2004-05-20 Matthias Gerlach Aryl- and heteroarylcarbonylpiperazines and their use for the treatment of benign and malignant oncoses

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
CAS Registry Number 1026968-94-4; STN Entry Date 10 June 2008; Methanone, [4-(3,5-dimethoxyphenyl)-1-piperazinyl]-9H-fluoren-9-yl- *
CAS Registry Number 432497-13-7; STN Entry Date 20 June 2002; 1-Piperazinecarboxylic acid, 4-(10H-phenothiazin-10-ylcarbonyl)-, ethyl ester *
CAS Registry Number 432528-56-8; STN Entry Date 20 June 2002; Methanone, [4-(4-nitrophenyl)-1-piperazinyl]-10H-phenothiazin-10-yl- *
CAS Registry Number 433947-75-2; STN Entry Date 26 June 2002; Methanone, [4-(4-fluorophenyl)-1-piperazinyl]-10H-phenothiazine-10-yl- *
CAS Registry Number 852704-21-3; STN Entry Date 22 June 2005; Methanone, 9H-fluoren-9-yl(4-phenyl-1-piperazinyl)- *
CAS Registry Number 873579-51-2; STN Entry Date 6 February 2006; 10H-Phenothiazine, 10-[[4-(5-chloro-2-methylphenyl)-1-piperazinyl]carbonyl]- *
CAS Registry Number 927053-66-5; STN Entry Date 18 March 2007; Methanone, 9H-fluoren-9-yl[4-(2-pyridinyl)-1-piperazinyl]- *
CAS Registry Number 927070-82-4; STN Entry Date 18 March 2007; Methanone, 9H-fluoren-9-yl[4-(4-nitrophenyl)-1-piperazinyl]- *
CAS Registry Number 927077-37-0; STN Entry Date 18 March 2007; Methanone, 9H-fluoren-9-yl[4-(2-pyrimidinyl)-1-piperazinyl]- *
CAS Registry Number 927604-97-5; STN Entry Date 20 March 2007; 1-Piperazinecarboxylic acid, 4-(9H-fluoren-9-ylcarbonyl)-, 1,1-dimethylethyl ester *

Also Published As

Publication number Publication date
WO2018033918A1 (en) 2018-02-22
CA3034211A1 (en) 2018-02-22
US20220098179A1 (en) 2022-03-31
US11084807B2 (en) 2021-08-10
JP7471818B2 (ja) 2024-04-22
US20200031815A1 (en) 2020-01-30
JP2019524789A (ja) 2019-09-05
AU2017311691A1 (en) 2019-04-04
US12162868B2 (en) 2024-12-10
CN109641884A (zh) 2019-04-16
CN109641884B (zh) 2024-01-02

Similar Documents

Publication Publication Date Title
AU2017311691B2 (en) Piperazine derivatives, pharmaceutical compositions and methods of use thereof
JP7030093B2 (ja) オキサチアジン様化合物を作製する方法
CN109952300A (zh) 作为吲哚胺2,3-二加氧酶和/或色氨酸2,3-二加氧酶选择性抑制剂的新颖的5或8-取代的咪唑并[1,5-a]吡啶
CN111410661A (zh) 帽依赖性内切核酸酶抑制剂及其用途
WO2012109423A1 (en) Method of inhibiting hamartoma tumor cells
ES2331153T3 (es) Compuestos de n-sulfonilaminofeniletil-2-fenoxiacetamida sustituidos.
JPH11269140A (ja) 分化誘導剤
KR20110136888A (ko) 퀴녹살린 유도체 및 양성 및 악성 종양 질병 치료를 위한 이의 용도
AU2006322844A1 (en) Chemical derivatives of jasmonate, pharmaceutical compositions and methods of use thereof
JP2007501267A (ja) 新規イミダゾール誘導体、その製造法及びその医薬としての使用
CN114805223B (zh) 一种用于抑制egfr的2，4-二取代喹唑啉类化合物及制备方法及应用
CN113292484B (zh) 3-(4-甲基哌啶-1-基)-3-苄基脲类化合物及其类似物、制备方法及应用
EP3481806B1 (en) 4-anilino-quinoline compounds as anti-cancer agents
KR20120074264A (ko) 헤테로사이클릭 치환된 아카르다이트 유도체 및 그 용도
CN113845484B (zh) 喹唑啉类小分子抑制剂及其在抗肿瘤药物中的应用
TW201917127A (zh) 用於抑制ａｄａｍ９活性之化合物、其醫藥組合物及其用途
EP4442684A1 (en) A class of pyrimidine compounds, and preparation method therefor and use thereof
CN110049768A (zh) 酚噻嗪衍生物及其使用方法
CN114907193A (zh) 一种基于Claisen重排反应的多酚类化合物及其制备方法和应用
CN114907190A (zh) 一种基于间位取代苯酚的多酚类化合物及制备方法和应用
CN113549046B (zh) 一种双联苄地钱素s衍生物及其制备方法和应用
CN105017034A (zh) 氨基醇类化合物、其制备方法、包含此类化合物的药物组合物及其用途
CN104496918B (zh) 吡嗪衍生物及其用途
CN104529833B (zh) 取代的环丁烷羧酸类化合物及其用途
CN117586330A (zh) 一种新型核苷衍生物及其药物组合物和用途

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)